Insights

Why Alkermes Stock Is Jumping Today

What happened
Shares of Alkermes (NASDAQ: ALKS) were jumping 11.9% as of 12:25 p.m. ET on Wednesday. The solid gain came after the drugmaker announced its first-quarter results before the market open.
Alkermes reported Q1 revenue of $278.5 million, up 10.8% year over year. This result handily beat the consensus estimate of $252.6 million.
The company generated earnings of $19.6 million, or $0.12 per share, in the first quarter on a non-GAAP (adjusted) basis. The average analysts’ estimate was for non-GAAP earnings of $0.01 per share. In the same period of 2021, Alkermes posted non-GAAP earnings of $17.8 million, or $0.11 per share.
So what
Investors tend to reward better-than-expected results. And Alkermes delivered the goods in the first quarter. However, the company’s upward trajectory is more important than the snapshot of its performance in one quarter.
Alkermes CEO Richard Pops said the company is seeing early utilization trends and feedback from healthcare professionals for antipsychotic drug Lybalvi that are encouraging. That could bode well for the drug’s commercial prospects. Lybalvi launched in October 2021 and raked in $13.9 million in Q1 sales.
The company’s other two approved drugs also continue to perform well. First-quarter sales of Vivitrol, which is used to treat opioid and alcohol dependence, rose 14% year over year to $84.9 million. Sales of antipsychotic drug Aristada jumped 31% to $72.5 million. 

Image source: Getty Images.

Now what
One key thing to watch with Alkermes in the near future is the outcome of the binding arbitration with Johnson & Johnson’s Janssen unit that began earlier this month. Alkermes is contesting Janssen’s partial termination of royalty agreements for several drugs that use the company’s NanoCrystal technology. 
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Alkermes and Johnson & Johnson. The Motley Fool has a disclosure policy. –

What happened

Shares of Alkermes (NASDAQ: ALKS) were jumping 11.9% as of 12:25 p.m. ET on Wednesday. The solid gain came after the drugmaker announced its first-quarter results before the market open.

Alkermes reported Q1 revenue of $278.5 million, up 10.8% year over year. This result handily beat the consensus estimate of $252.6 million.

The company generated earnings of $19.6 million, or $0.12 per share, in the first quarter on a non-GAAP (adjusted) basis. The average analysts’ estimate was for non-GAAP earnings of $0.01 per share. In the same period of 2021, Alkermes posted non-GAAP earnings of $17.8 million, or $0.11 per share.

So what

Investors tend to reward better-than-expected results. And Alkermes delivered the goods in the first quarter. However, the company’s upward trajectory is more important than the snapshot of its performance in one quarter.

Alkermes CEO Richard Pops said the company is seeing early utilization trends and feedback from healthcare professionals for antipsychotic drug Lybalvi that are encouraging. That could bode well for the drug’s commercial prospects. Lybalvi launched in October 2021 and raked in $13.9 million in Q1 sales.

The company’s other two approved drugs also continue to perform well. First-quarter sales of Vivitrol, which is used to treat opioid and alcohol dependence, rose 14% year over year to $84.9 million. Sales of antipsychotic drug Aristada jumped 31% to $72.5 million. 

Image source: Getty Images.

Now what

One key thing to watch with Alkermes in the near future is the outcome of the binding arbitration with Johnson & Johnson‘s Janssen unit that began earlier this month. Alkermes is contesting Janssen’s partial termination of royalty agreements for several drugs that use the company’s NanoCrystal technology. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Alkermes and Johnson & Johnson. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!